Nivolumab for adjuvant and neoadjuvant treatment of localised renal cell carcinoma
Nivolumab is in clinical development for the adjuvant and neoadjuvant treatment of adults with localised renal cell carcinoma (RCC) who are undergoing surgical removal of a kidney. RCC is a common form of kidney cancer caused by the growth of a tumour in the cells lining the inside of small vessels in the kidney, known […]
Pegcetacoplan for treating geographic atrophy
Pegcetacoplan is in clinical development for the treatment of geographic atrophy of the macula, secondary to age-related macular degeneration (AMD). AMD is an eye disease that most commonly occurs in people aged over 70 years that affects the middle part of the vision. Some patients with AMD will develop geographic atrophy, which is an advanced […]
Lecanemab for treating early Alzheimer's disease
Lecanemab is currently in clinical development for the treatment of early Alzheimer’s disease (AD). AD is a progressive neurological disease which is caused by loss of function and death of neurones in the brain. It is the most common type of dementia.